Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
New data with SRP-9001 look decent, but filing plans remain uncertain.
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.